– SPAIN, Barcelona / USA, CA – Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, announced the appointment of Dr. Chuck Carignan (M.D.) as chairman of the Board of Directors, bringing extensive clinical, product development, commercialization, and leadership expertise to the role.
About Dr. Charles Carignan, M.D.
Dr. Chuck Carignan has served on committees of the U.S. Food and Drug Administration, the Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development. Additionally, he has led multiple successful corporations, including being the founding president and CEO of NinePoint Medical, president and CEO of BionX Medical, and CEO of SoniVie Inc. Prior roles include EVP and CMO at Novasys Medical, CMO of Endosurgery at Boston Scientific, and vice president of clinical research and medical affairs at Conceptus, Inc. He serves as the executive chairman of Cairdac, chairman of SamanTree Medical, and a director of Biothea and Prothea.
Dr. Chuck Carignan said, “Beginning with the unique ANA Funnel Catheter technology, Anaconda has the opportunity to literally change the shape of the mechanical thrombectomy field. I am honored to join the board to actively contribute to the next phase of the company’s successes by working closely with Trent and the rest of the board.”
About Anaconda Biomed
Anaconda Biomed is an innovative medical technology company dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health.
For more information: https://anaconda.bio
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.